-
Prilenia shares HD trial data with CHDI to help future research
Latest News
-
Gene silencing drug safe in ALS patients… bring on Huntington's disease trials
Gene silencing drug injected into spinal fluid in ALS patients proves safe. Good news for similar planned HD trials.
-
A DNA repair protein modifies the stability of long CAG tracts in the Huntington's disease gene
DNA repair is a critical process to cells, but errors in this process might explain 'repeat instability' in HD
-
Landmark study puts Huntington's disease trials on TRACK
Final results from the TRACK-HD study show very specific changes in HD. We're ready for trials: bring on the drugs!
-
Splicing with danger: a new way of thinking about the harmful Huntington's disease protein
Researchers discover a new way harmful fragments of the huntingtin protein are made in neurons.
-
Proposed Huntington's disease 'biomarker' is not useful, new study suggests
New study shows a blood chemical called '8OHdG' is not a good biomarker for HD. Bad news?
-
Is access to predictive genetic testing for Huntington's disease a problem?
Is access to predictive genetic testing for Huntington's disease a problem? A UBC study says it is.
-
HD Therapeutics Conference 2013 Updates: Day 3
Final day of our coverage of the Huntington's Disease Therapeutics Conference 2013
-
HD Therapeutics Conference 2013 Updates: Day 2
Day 2 of our coverage of the Huntington's Disease Therapeutics Conference
-
Major Roche-Isis deal boosts Huntington's disease gene silencing
'ASO' gene silencing drugs for HD boosted by major deal between Isis Pharmaceuticals and Roche
-
HD Therapeutics Conference 2013 Updates: Day 1
Day 1 of our coverage of the Huntington's Disease Therapeutics Conference
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Show 9 more Show less
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
